GlassScriptPhysician profile
Charles D Malinick
NPI 1518959162
$4,942.74
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,550 · 2020: $1,186 · 2021: $1,340 · 2022: $867.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $842.88 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $774.14 | 2019-2022 | |
| Allergan, INC. | $724.67 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $704.92 | 2019-2022 | |
| Lundbeck LLC | $271.76 | 2019-2021 | |
| Abbvie INC. | $241.03 | 2021-2022 | |
| Adlon Therapeutics L.P. | $230.19 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $222.75 | 2021-2022 | |
| Alkermes, INC. | $195.83 | 2019-2022 | |
| Bausch Health US, LLC | $175.77 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $167.20 | 2019-2022 | |
| Eisai INC. | $87.93 | 2020-2021 | |
| Tris Pharma INC | $73.18 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $62.12 | 2019 | |
| Jazz Pharmaceuticals INC. | $37.89 | 2020-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.81 | 2020-2022 | |
| Axsome Therapeutics, INC. | $30.06 | 2022 | |
| Merck Sharp & Dohme LLC | $24.75 | 2021 | |
| Livanova USA, INC. | $22.97 | 2021 | |
| Neos Therapeutics, LP | $14.89 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Malinick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.